The global recombinant noglycosylated proteins biosimilars market is expected to grow at a CAGR of 16.2% during the forecast period, from 2021 to 2030. The growth of this market is attributed to the increasing demand for cost-effective and affordable drugs, which are not available in the market due to patent protection. The major players in this market are Novo Nordisk A/S (Denmark), Sanofi S.A (France), Eli Lilly and Company (US), Pfizer Inc, Merck & Co., Inc, AstraZeneca plc, Roche Holding AG, Johnson & Johnson Services Inc, AbbVie Inc, Amgen Inc, Biogen Idec MA INC, Bayer AG and Novartis International AG among others.
Some Of The Growth Factors Of This Market:
- The increasing prevalence of chronic diseases such as cancer, diabetes, and cardiovascular diseases is driving the demand for recombinant non-glycosylated proteins biosimilars in the global market.
- The increasing number of biologics entering into clinical trials and approval by regulatory authorities is also driving the growth of this market globally.
- Increasing awareness about biosimilars among physicians and patients will also drive this market globally.
- Increasing government support for research and development activities in developing countries will also drive this market globally.
Industry Growth Insights published a new data on “Recombinant Non-Glycosylated Proteins Biosimilars Market”. The research report is titled “Recombinant Non-Glycosylated Proteins Biosimilars Market research by Types (Insulin, rHGH, Interferon), By Applications (Oncology, Chronic Diseases, Autoimmune Diseases, Blood Disorders, Growth Hormone Deficiency, Infectious Diseases, Other Diseases), By Players/Companies Sandoz, Pfizer, Teva Pahrmaceutical, Celltrion, Biocon, Amgen, Samsung Biologics, Mylan, Dr. Reddy's Laboratories, Stada Arzneimittel AG”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Recombinant Non-Glycosylated Proteins Biosimilars Market Research Report
By Type
Insulin, rHGH, Interferon
By Application
Oncology, Chronic Diseases, Autoimmune Diseases, Blood Disorders, Growth Hormone Deficiency, Infectious Diseases, Other Diseases
By Companies
Sandoz, Pfizer, Teva Pahrmaceutical, Celltrion, Biocon, Amgen, Samsung Biologics, Mylan, Dr. Reddy's Laboratories, Stada Arzneimittel AG
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
242
Number of Tables & Figures
170
Customization Available
Yes, the report can be customized as per your need.
Global Recombinant Non-Glycosylated Proteins Biosimilars Market Report Segments:
The global Recombinant Non-Glycosylated Proteins Biosimilars market is segmented on the basis of:
Types
Insulin, rHGH, Interferon
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Oncology, Chronic Diseases, Autoimmune Diseases, Blood Disorders, Growth Hormone Deficiency, Infectious Diseases, Other Diseases
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Sandoz
- Pfizer
- Teva Pahrmaceutical
- Celltrion
- Biocon
- Amgen
- Samsung Biologics
- Mylan
- Dr. Reddy's Laboratories
- Stada Arzneimittel AG
Highlights of The Recombinant Non-Glycosylated Proteins Biosimilars Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Insulin
- rHGH
- Interferon
- By Application:
- Oncology
- Chronic Diseases
- Autoimmune Diseases
- Blood Disorders
- Growth Hormone Deficiency
- Infectious Diseases
- Other Diseases
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Recombinant Non-Glycosylated Proteins Biosimilars Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Recombinant non-glycosylated proteins biosimilars are proteins that have been produced by recombinant DNA technology. These proteins are identical to the original protein, but they do not contain glycosylation.
Some of the major players in the recombinant non-glycosylated proteins biosimilars market are Sandoz, Pfizer, Teva Pahrmaceutical, Celltrion, Biocon, Amgen, Samsung Biologics, Mylan, Dr. Reddy's Laboratories, Stada Arzneimittel AG.
The recombinant non-glycosylated proteins biosimilars market is expected to grow at a compound annual growth rate of 16.2%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Recombinant Non-Glycosylated Proteins Biosimilars Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Recombinant Non-Glycosylated Proteins Biosimilars Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Recombinant Non-Glycosylated Proteins Biosimilars Market - Supply Chain
4.5. Global Recombinant Non-Glycosylated Proteins Biosimilars Market Forecast
4.5.1. Recombinant Non-Glycosylated Proteins Biosimilars Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Recombinant Non-Glycosylated Proteins Biosimilars Market Size (000 Units) and Y-o-Y Growth
4.5.3. Recombinant Non-Glycosylated Proteins Biosimilars Market Absolute $ Opportunity
5. Global Recombinant Non-Glycosylated Proteins Biosimilars Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Recombinant Non-Glycosylated Proteins Biosimilars Market Size and Volume Forecast by Type
5.3.1. Insulin
5.3.2. rHGH
5.3.3. Interferon
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Recombinant Non-Glycosylated Proteins Biosimilars Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Recombinant Non-Glycosylated Proteins Biosimilars Market Size and Volume Forecast by Application
6.3.1. Oncology
6.3.2. Chronic Diseases
6.3.3. Autoimmune Diseases
6.3.4. Blood Disorders
6.3.5. Growth Hormone Deficiency
6.3.6. Infectious Diseases
6.3.7. Other Diseases
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Recombinant Non-Glycosylated Proteins Biosimilars Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Recombinant Non-Glycosylated Proteins Biosimilars Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Recombinant Non-Glycosylated Proteins Biosimilars Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Recombinant Non-Glycosylated Proteins Biosimilars Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Recombinant Non-Glycosylated Proteins Biosimilars Demand Share Forecast, 2019-2026
9. North America Recombinant Non-Glycosylated Proteins Biosimilars Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Recombinant Non-Glycosylated Proteins Biosimilars Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Recombinant Non-Glycosylated Proteins Biosimilars Market Size and Volume Forecast by Application
9.4.1. Oncology
9.4.2. Chronic Diseases
9.4.3. Autoimmune Diseases
9.4.4. Blood Disorders
9.4.5. Growth Hormone Deficiency
9.4.6. Infectious Diseases
9.4.7. Other Diseases
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Recombinant Non-Glycosylated Proteins Biosimilars Market Size and Volume Forecast by Type
9.7.1. Insulin
9.7.2. rHGH
9.7.3. Interferon
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Recombinant Non-Glycosylated Proteins Biosimilars Demand Share Forecast, 2019-2026
10. Latin America Recombinant Non-Glycosylated Proteins Biosimilars Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Recombinant Non-Glycosylated Proteins Biosimilars Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Recombinant Non-Glycosylated Proteins Biosimilars Market Size and Volume Forecast by Application
10.4.1. Oncology
10.4.2. Chronic Diseases
10.4.3. Autoimmune Diseases
10.4.4. Blood Disorders
10.4.5. Growth Hormone Deficiency
10.4.6. Infectious Diseases
10.4.7. Other Diseases
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Recombinant Non-Glycosylated Proteins Biosimilars Market Size and Volume Forecast by Type
10.7.1. Insulin
10.7.2. rHGH
10.7.3. Interferon
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Recombinant Non-Glycosylated Proteins Biosimilars Demand Share Forecast, 2019-2026
11. Europe Recombinant Non-Glycosylated Proteins Biosimilars Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Recombinant Non-Glycosylated Proteins Biosimilars Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Recombinant Non-Glycosylated Proteins Biosimilars Market Size and Volume Forecast by Application
11.4.1. Oncology
11.4.2. Chronic Diseases
11.4.3. Autoimmune Diseases
11.4.4. Blood Disorders
11.4.5. Growth Hormone Deficiency
11.4.6. Infectious Diseases
11.4.7. Other Diseases
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Recombinant Non-Glycosylated Proteins Biosimilars Market Size and Volume Forecast by Type
11.7.1. Insulin
11.7.2. rHGH
11.7.3. Interferon
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Recombinant Non-Glycosylated Proteins Biosimilars Demand Share, 2019-2026
12. Asia Pacific Recombinant Non-Glycosylated Proteins Biosimilars Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Recombinant Non-Glycosylated Proteins Biosimilars Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Recombinant Non-Glycosylated Proteins Biosimilars Market Size and Volume Forecast by Application
12.4.1. Oncology
12.4.2. Chronic Diseases
12.4.3. Autoimmune Diseases
12.4.4. Blood Disorders
12.4.5. Growth Hormone Deficiency
12.4.6. Infectious Diseases
12.4.7. Other Diseases
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Recombinant Non-Glycosylated Proteins Biosimilars Market Size and Volume Forecast by Type
12.7.1. Insulin
12.7.2. rHGH
12.7.3. Interferon
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Recombinant Non-Glycosylated Proteins Biosimilars Demand Share, 2019-2026
13. Middle East & Africa Recombinant Non-Glycosylated Proteins Biosimilars Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Recombinant Non-Glycosylated Proteins Biosimilars Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Recombinant Non-Glycosylated Proteins Biosimilars Market Size and Volume Forecast by Application
13.4.1. Oncology
13.4.2. Chronic Diseases
13.4.3. Autoimmune Diseases
13.4.4. Blood Disorders
13.4.5. Growth Hormone Deficiency
13.4.6. Infectious Diseases
13.4.7. Other Diseases
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Recombinant Non-Glycosylated Proteins Biosimilars Market Size and Volume Forecast by Type
13.7.1. Insulin
13.7.2. rHGH
13.7.3. Interferon
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Recombinant Non-Glycosylated Proteins Biosimilars Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Recombinant Non-Glycosylated Proteins Biosimilars Market: Market Share Analysis
14.2. Recombinant Non-Glycosylated Proteins Biosimilars Distributors and Customers
14.3. Recombinant Non-Glycosylated Proteins Biosimilars Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Sandoz
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Pfizer
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Teva Pahrmaceutical
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Celltrion
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Biocon
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Amgen
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Samsung Biologics
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Mylan
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Dr. Reddy's Laboratories
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Stada Arzneimittel AG
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
&nbs
